Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Journal article
Waerlop G. et al, (2023), J Immunol Methods, 523
Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.
Journal article
Mitsi E. et al, (2023), Nat Commun, 14
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Journal article
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Journal article
Port JR. et al, (2023), Nat Commun, 14
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Journal article
Ramasamy MN. et al, (2023), Lancet Microbe
Generation and Characterisation of Monoclonal Antibodies against Nairobi Sheep Disease Virus Nucleoprotein.
Journal article
Maze EA. et al, (2023), Viruses, 15
The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.
Journal article
Dzau V. et al, (2023), Lancet
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.
Journal article
Neale I. et al, (2023), mBio
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.
Journal article
Hornsby H. et al, (2023), Nat Commun, 14
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Journal article
Costa Clemens SA. et al, (2023), Hum Vaccin Immunother, 19
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Journal article
Barnes E. et al, (2023), Nat Med, 29, 1760 - 1774
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Journal article
Kelly E. et al, (2023), J Infect
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Journal article
Kaplonek P. et al, (2023), Nat Immunol
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.
Journal article
Yin Z. et al, (2023), Cell Rep, 42
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Journal article
Koen AL. et al, (2023), Vaccine, 41, 3486 - 3492
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2023), J Infect
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model.
Journal article
Saunders JE. et al, (2023), EBioMedicine, 90
ChAdOx1 nCoV-19 vaccination generates spike-specific CD8+ T cells in aged mice.
Journal article
Foster WS. et al, (2023), Immunol Cell Biol